Skip to main content
Premium Trial:

Request an Annual Quote

Former Sequenom Exec Pleads Guilty; Sentencing Scheduled for August

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sequenom's former senior vice president of research and develop has pled guilty to a charge that she made false statements about the company's prenatal test for Down syndrome and will be sentenced on Aug. 30, the firm disclosed in a document filed with the US Securities and Exchange Commission after the close of the market on Tuesday.

Elizabeth Dragon had been charged by the US Securities and Exchange Commission in June with making "materially false and misleading statements" about Sequenom's Trisomy 21 test, which continues to be in development, and artificially inflating the company's stock price.

In its SEC filing, the company said that Dragon will be sentenced in the US District Court for the Southern District of California.

As a result of the mishandling of the data for the test, Dragon, Sequenom's former President and CEO, Harry Stylli, and other executives were fired last September by the company.

In May, the company said that it will continue to develop the Trisomy 21 test and "that following extensive scientific experimentation, we have decided to proceed with a purely DNA-based method for the detection of the Trisomy 21 aneuploidy using massively parallel sequencing instead of our proprietary MassARRAY platform."

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.